http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2005514355-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 |
| filingDate | 2002-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2005514355-A |
| titleOfInvention | Pharmaceutical formulation comprising bicalutamide |
| abstract | The present invention relates to 4′-cyano-α ′, α ′, α′-trifluoro-3- (4-fluorophenylsulfonyl) -2-2 in a solid dispersion with an enteric polymer having a pKa of 3-6. Hydroxy-2-methylpropiono-m-toluizide or a pharmaceutically acceptable salt or solvate thereof, comprising an anti-estrogen (eg tamoxifen citrate) and / or an aromatase inhibitor (eg anastrozole) ) Further comprising a medicament for administration to a patient. The present invention also relates to pharmaceutical dosages of the above drugs and antiestrogens / aromatase inhibitors provided by such formulations. The advantage increases the bioavailability of the drug; 4′-cyano-α ′, α ′, α′-trifluoro-3- (4-fluorophenylsulfonyl) -2-hydroxy-2-methylpropiono-m- Reduce patient-to-patient variability in toluidide plasma concentration; increase the storage stability of the drug; and / or treat prostate cancer in the patient and / or reduce its risk while gynecomastia, chest tenderness Treating and / or preventing at least one side effect selected from hot flashes, impotence, reduced libido. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011513705-A |
| priorityDate | 2001-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 119.